Advertisement

Topics

Tenet Reports Results for the Fourth Quarter Ended December 31, 2016 and Issues Outlook for 2017

16:15 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Reported a net loss from continuing operations of $187 million or $1.88 per share in 2016 and a net loss from continuing operations of $79 million or $0.79 per share in the fourth quarter. Adjusted EB...

Other Sources for this Article

Tenet Healthcare Corporation
Corporate Communications
Charles Nicolas, 469-893-2640
mediarelations@tenethealth.com
or
Investor Relations
Brendan Strong, 469-893-6992
investorrelations@tenethealth.com

NEXT ARTICLE

More From BioPortfolio on "Tenet Reports Results for the Fourth Quarter Ended December 31, 2016 and Issues Outlook for 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...